These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 20451251)

  • 41. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
    Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C; Clissa C; Stanzani M
    Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V; Neokleous N; Agapidou A; Economou M; Vetsiou E; Teli A; Perifanis V
    Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
    [No Abstract]   [Full Text] [Related]  

  • 44. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
    Taher AT; Porter J; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Ros J; Zhang Y; Habr D; Cappellini MD
    Blood; 2012 Aug; 120(5):970-7. PubMed ID: 22589472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
    Porter JB; Lin KH; Beris P; Forni GL; Taher A; Habr D; Domokos G; Roubert B; Thein SL;
    Eur J Haematol; 2011 Oct; 87(4):338-48. PubMed ID: 21649735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
    Bruch HR; Dencausse Y; Heßling J; Michl G; Schlag R; Skorupa A; Schneider-Schranz C; Wolf S; Schulte C; Tesch H
    Oncol Res Treat; 2016; 39(7-8):424-31. PubMed ID: 27486873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
    Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
    Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
    Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
    Chandra J; Chaudhary H; Pemde H; Singh V; Dutta AK
    Ann Trop Paediatr; 2011; 31(1):47-51. PubMed ID: 21262109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delineating parameters of iron overload in MDS patients treated with deferasirox.
    Leitch HA
    Leuk Res; 2010 Dec; 34(12):1556-7. PubMed ID: 20719382
    [No Abstract]   [Full Text] [Related]  

  • 51. Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias.
    Kohgo Y; Urabe A; Kilinç Y; Agaoglu L; Warzocha K; Miyamura K; Lim LC; Glaser S; Wang C; Wiktor-Jedrzejczak W
    Acta Haematol; 2015; 134(4):233-42. PubMed ID: 26138856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
    Sarocchi M; Li J; Li X; Wu D; Montaño Figueroa E; Rodriguez MG; Hou M; Finelli C; Shi HX; Xiao Z; Oliva EN; Gercheva Kyuchukova L; Drummond M; Symeonidis A; Velazquez EJ; Rivoli G; Izquierdo M; Kolekar Y; Spallarossa P; Angelucci E
    Br J Haematol; 2024 May; 204(5):2049-2056. PubMed ID: 38343073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
    Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
    Ktena YP; Athanasiadou A; Lambrou G; Adamaki M; Moschovi M
    J Pediatr Hematol Oncol; 2013 Aug; 35(6):447-50. PubMed ID: 23669734
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
    Breccia M; Finsinger P; Loglisci G; Federico V; Santopietro M; Colafigli G; Petrucci L; Salaroli A; Serrao A; Latagliata R; Alimena G
    Ann Hematol; 2012 Sep; 91(9):1345-9. PubMed ID: 22569854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deferasirox: pharmacokinetics and clinical experience.
    Galanello R; Campus S; Origa R
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
    Jetsrisuparb A; Komvilaisak P; Wiangnon S; Jetsrisuparb C
    J Pediatr Hematol Oncol; 2010 Jul; 32(5):400-3. PubMed ID: 20505533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
    Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR
    Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK
    Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
    Yusuf B; McPhedran P; Brewster UC
    Am J Kidney Dis; 2008 Sep; 52(3):587-90. PubMed ID: 18534729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.